AURA Stock — Aura Biosciences Inc

Aura Biosciences Inc (AURA)

Updated October 16, 2026.

AURA is a Stock. Total return is -58.8% over the past 5 years, 136.5 points behind SPY at 77.7%.

Aura Biosciences is a clinical-stage biotechnology company developing precision therapies to treat solid tumors using a proprietary platform that combines virus-like particles with drugs or nucleic acids. Its lead candidate, bel-sar, is in late-stage clinical development for primary choroidal melanoma and other ocular cancers, with early-stage testing underway in bladder cancer and other solid tumor indications. The company does not currently distribute dividends and is primarily suited for investors seeking exposure to early-stage biotech development rather than current income.

AURA performance versus SPY

Price and return data through 2026-10-16.

Total return is -58.8% over the past 5 years, 136.5 points behind SPY at 77.7%. Over the past year its total return — price change plus distributions reinvested — is -1.4%. Its deepest 1-year drawdown was 32.6%.

AURA key facts

Asset type

Stock

Asset class

Equity

Inception date

10/29/2021

Distribution frequency

None

Last close

$6.10 (as of 2026-10-16)

Market cap

$632,599,335

Average volume

762443.0

Beta

0.413

Payout ratio

0.0%

EPS

$-1.75

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

AURA risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 32.6%.

Who may consider AURA — and who may not

It is a weaker fit for investors who need monthly cash flow (AURA does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on AURA

• All tickers starting with A

Tagged: Healthcare.

Frequently asked questions